Abstract
Introduction Needle-stick injuries (NSIs) are defined as the sharp point of a needle puncturing human skin. This article examines the risk and illustrates the burden of NSIs for workers in the healthcare, veterinary and research industries, and includes a sample survey population of workers in workplaces using needles.
Methods For the review component of this article, PubMed and Google Scholar were queried within the date range of 1998-2022, retrieving 1,437 results. A publicly available sample population dataset was and analyzed from British Columbia (n=30) on workplace needlestick injuries. The OSHA, WHO, and NIEHS guidelines were reviewed, and the WorkSafe BC injury database was searched using FIPPA requests.
Discussion Recapping remains a common practice despite decades of guidelines recommending against recapping. NSI research is underpowered and underrepresented in non-healthcare settings. NSIs lead to heightened anxiety, depression, and PTSD in workers and exposure to pathogens, toxic chemicals and permanent tissue damage. NSI annual reporting is likely an underestimate due to chronic underreporting, and the financial impact including work-loss and healthcare costs continues to rise. Current NSI prevention devices have limited uptake and thus, more affordable, versatile and efficient NSI-prevention devices are needed.
Relevance Due to COVID-19, healthcare workers are at a higher risk of receiving NSIs. Emphasis on safe needle handling practices is necessary to maintain workers physical and psychological safety, to protect workers using COVID-19 PPE on long shifts, and to deliver the high volume of vaccinations required to inoculate the global population.
Conclusion NSIs are detrimental to healthcare workers wellbeing, chronically underreported, and poorly surveyed. Areas of future research include determining more effective solutions to reduce NSIs, assessing the validity of NSI reporting systems, and integrating solutions with COVID-19 prevention and vaccination protocols.
Competing Interest Statement
Conflicts of interest: SYSL declares no conflict of interest. IN and JM declare that they own shares in a medical device and design company, DECAP R&D, which makes needle-safety products.
Funding Statement
No specific funding was allocated for this research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Source data were openly available before the initiation of the study : https://www.decaprandd.com/decap-whitepaper. All data produced in the present study are available upon reasonable request to the authors.
